selinexor + gemcitabine + oxaliplatin

Selinexor + gemcitabine + oxaliplatin is an investigational combination regimen used in clinical studies for the treatment of **relapsed or refractory diffuse large B-cell lymphoma (DLBCL)**, especially in patients with TP53 gene alterations[2][3][5][7]. - **Selinexor** is a first-in-class, orally administered, selective inhibitor of exportin-1 (XPO1), which blocks the nuclear export of tumor suppressor proteins and sensitizes cancer cells to DNA-damaging chemotherapeutics by promoting cell cycle arrest and apoptosis[1][5]. - **Gemcitabine** is a nucleoside analog and cytotoxic chemotherapy that interferes with DNA synthesis, leading to apoptosis[2][5]. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that induces DNA cross-linking and apoptosis[5][7]. Combined, this regimen aims for synergistic cell cycle arrest and enhancement of DNA damage responses in aggressive lymphomas. Studies have shown objective response rates up to 60% for selinexor plus salvage regimens in R/R DLBCL, with responses linked to increased apoptosis and cell cycle checkpoint modulation[5][7]. The regimen is being tested as a second-line therapy and for salvage in patients not candidates for CAR-T therapy[2][3][5][7].

Other names

selinexor + gemcitabine + oxaliplatinS-R-GemOx